The most reported treatment-related adverse events (TRAEs) in the ITT population were neutropenia, leukopenia, alopecia, elevated alanine aminotransaminase (ALT) and elevated aspartate aminotransferase (AST) (Table 5). This evidence concerns the gene GPT and neutropenia.